Inhaled NovoSeven Dosing
NovoSeven (recombinant activated factor VII) is NOT administered via inhalation—it is given exclusively by intravenous bolus injection. The question appears to contain a fundamental error regarding the route of administration.
Correct Administration Route
NovoSeven is administered intravenously only 1. After reconstitution with histidine diluent, the final solution contains approximately 1 mg/mL (1000 micrograms/mL) and must be given as an IV bolus 1.
Standard Dosing Regimens (Intravenous)
For Hemophilia A or B with Inhibitors
The approved dosing is 90 micrograms/kg IV every 2-3 hours until bleeding cessation 2, 1. However, current evidence supports flexibility:
- Standard regimen: 90 micrograms/kg every 2-3 hours
- Single high-dose alternative: 270 micrograms/kg as a single dose (approved in EU) 3, 4
The 2024 ISTH guidelines suggest either 3 doses of 90 micrograms/kg at 3-hour intervals OR a single dose of 270 micrograms/kg for joint bleeding, noting these options appear equivalent in efficacy 3. The single-dose regimen offers lower treatment burden, though the 3-dose scheme allows early discontinuation if bleeding stops quickly 3.
Key Dosing Considerations
Real-world data demonstrates that doses exceeding 90 micrograms/kg are commonly used: Analysis of 61,734 doses showed 52% exceeded 120 micrograms/kg, 37% exceeded 160 micrograms/kg, and 15% exceeded 240 micrograms/kg, all without safety concerns 5.
For Other Indications (IV only)
- Congenital Factor VII deficiency: 15-30 micrograms/kg every 6 hours initially, then every 12 hours 2
- Glanzmann's thrombasthenia with antibodies: 80-120 micrograms/kg bolus before/during procedures, with 2 hours between doses 2
- Acquired hemophilia: Mean dose 90 micrograms/kg (range 31-197 micrograms/kg) 1
Important Safety Notes
- With emicizumab prophylaxis: rFVIIa is the preferred bypassing agent due to thrombotic risk with aPCC 3, 6
- Prerequisites for efficacy: Fibrinogen ≥1 g/L, platelets ≥50 × 10⁹/L, pH ≥7.2, temperature >34°C 2
- Thrombotic risk: Very low (0.11% in hemophilia with inhibitors, <1:25,000 in approved indications) 7
There is no inhaled formulation of NovoSeven available or approved. If you intended to ask about a different medication or route, please clarify the question.